Xbrane’s US Approval Bid For Ranibizumab Biosimilar Stalls Again After FDA Review

Firm Had Readied Capital Structure, Liquidity Measures Before Ranibizumab Action Date

 
• By Dean Rudge
  
Business man in suit looking at a red arrow pointing downwards, crashing through the ground in front of him
• Source: Shutterstock

More from Biosimilars

More from Generics Bulletin